,0
symbol,UROV
price,16.02
beta,0.0
volAvg,83950
mktCap,507191616
lastDiv,0.0
range,6.55-16.08
changes,7.74
companyName,Urovant Sciences Ltd
currency,USD
cik,0001740547
isin,BMG9381B1081
cusip,G9381B108
exchange,NasdaqGS
exchangeShortName,NASDAQ
industry,Biotechnology
website,https://urovant.com/
description,"Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. The company is headquartered in Irvine, California and currently employs 39 full-time employees. The firm is focused on developing and commercializing therapies for urologic conditions. Its product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist. is focused on evaluating vibegron in its over 1,400 patients, pivotal phase-3 clinical trial for the treatment of overactive bladder (OAB). The Companyâ€™s subsidiaries include Urovant Sciences, Inc., Urovant Holdings Limited, and Urovant Sciences GmbH."
ceo,Mr. Keith Katkin
sector,Healthcare
country,US
fullTimeEmployees,70
phone,19492266029
address,5281 California Ave Ste 100
city,Irvine
state,CALIFORNIA
zip,
dcfDiff,
dcf,9.83033
image,https://financialmodelingprep.com/image-stock/UROV.png
ipoDate,2018-09-27
defaultImage,False
